2 months ago
Celtic begin our Premier Sports campaign this evening with a difficult task against Jim Goodwin's Dundee United at Tannadice later this afternoon.
It's the venue where Martin O'Neill last experienced the bitter taste of defeat before galvanising the team for a sensational ***** le run in which ended with a spectacular double.
That defeat at Tannadice was played on an atrocious playing surface which will not be the case today and with three of our new signings likely to start with another on the bench, there will certainly be a greater goal threat from Celtic on this occasion.
Celtic Manager Martin O Neill Celtic Training and press conference, PK, Pressekonferenz Football, Lennoxtown Training Ground, East Dunbartonshire, Scotland, UK – 14 Aug 2026East Dumbartonshire Lennoxtown Training Ground United Kingdom PUBLICATIONxINxGERxSUIxAUTxHUNxGRExMLTxCYPxROUxBULxUAExKSAxCHNxDENxINDxITAxPORxESPxSWExTURxMEXxCOLxVENxPERxECUxBRAxARGxCHIxURUxPARxPANxONLY Copyright: xStuartxWallace/Shutterstockx 17069852cb
Celtic also lost at Tannadice last season during the ill-fated and ill-considered tenure of Wilfried Nancy do we clearly are due a triumph in the City of Discovery where we also lost across the road last term with Brendan Rodgers in charge that afternoon.
#tannadice #last #ground
It's the venue where Martin O'Neill last experienced the bitter taste of defeat before galvanising the team for a sensational ***** le run in which ended with a spectacular double.
That defeat at Tannadice was played on an atrocious playing surface which will not be the case today and with three of our new signings likely to start with another on the bench, there will certainly be a greater goal threat from Celtic on this occasion.
Celtic Manager Martin O Neill Celtic Training and press conference, PK, Pressekonferenz Football, Lennoxtown Training Ground, East Dunbartonshire, Scotland, UK – 14 Aug 2026East Dumbartonshire Lennoxtown Training Ground United Kingdom PUBLICATIONxINxGERxSUIxAUTxHUNxGRExMLTxCYPxROUxBULxUAExKSAxCHNxDENxINDxITAxPORxESPxSWExTURxMEXxCOLxVENxPERxECUxBRAxARGxCHIxURUxPARxPANxONLY Copyright: xStuartxWallace/Shutterstockx 17069852cb
Celtic also lost at Tannadice last season during the ill-fated and ill-considered tenure of Wilfried Nancy do we clearly are due a triumph in the City of Discovery where we also lost across the road last term with Brendan Rodgers in charge that afternoon.
#tannadice #last #ground
2 months ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted argenx SE (NASDAQ:ARGX). argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the United States and internationally. On August 03, 2026, argenx SE (NASDAQ:ARGX) closed at $830.79 per share. The one-month return of argenx SE (NASDAQ:ARGX) was -9.69% and its shares gained 23.10% over the past 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $51.66 billion with a 52-week trading range between $631.47 - $953.58.
Baron Health Care Fund stated the following regarding argenx SE (NASDAQ:ARGX) in its Q2 2026 investor letter:
"Biotechnology company argenx SE (NASDAQ:ARGX) is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose after a period of prior weakness, which may have been partly driven by the retirement of longtime CEO Tim Van Hauwermeiren in early 2026. We view the transition to Karen Massey, who previously led the company's operations, as largely non-disruptive and believe she is well positioned to continue executing the company's strategy. Shares also benefited from optimism ahead of several clinical readouts, including data from studies of Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, expected in the third quarter of 2026, as well as empasibrupart in multifocal motor neuropathy, expected in the fourth quarter of 2026. Vyvgart continues to launch well in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, where we believe it has established itself as an important treatment option. We expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions over time and remain encouraged by argenx's pipeline progress."
#care #argx #baron #vyvgart
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted argenx SE (NASDAQ:ARGX). argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the United States and internationally. On August 03, 2026, argenx SE (NASDAQ:ARGX) closed at $830.79 per share. The one-month return of argenx SE (NASDAQ:ARGX) was -9.69% and its shares gained 23.10% over the past 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $51.66 billion with a 52-week trading range between $631.47 - $953.58.
Baron Health Care Fund stated the following regarding argenx SE (NASDAQ:ARGX) in its Q2 2026 investor letter:
"Biotechnology company argenx SE (NASDAQ:ARGX) is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose after a period of prior weakness, which may have been partly driven by the retirement of longtime CEO Tim Van Hauwermeiren in early 2026. We view the transition to Karen Massey, who previously led the company's operations, as largely non-disruptive and believe she is well positioned to continue executing the company's strategy. Shares also benefited from optimism ahead of several clinical readouts, including data from studies of Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, expected in the third quarter of 2026, as well as empasibrupart in multifocal motor neuropathy, expected in the fourth quarter of 2026. Vyvgart continues to launch well in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, where we believe it has established itself as an important treatment option. We expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions over time and remain encouraged by argenx's pipeline progress."
#care #argx #baron #vyvgart
2 months ago
Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27.
FBRX saw significant price movement beginning June 29, weeks before the public announcement.
Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action.
This case exemplifies how pre-announcement trading patterns can signal forthcoming M&A activity, offering educational insight into market behavior.
Author's Note: Today's Chart of the Day is for educational purposes only. I want to illustrate that before any M&A is announced to the public, you will sometimes see an individual who has insider information acting on it.
#fbrx #price
FBRX saw significant price movement beginning June 29, weeks before the public announcement.
Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action.
This case exemplifies how pre-announcement trading patterns can signal forthcoming M&A activity, offering educational insight into market behavior.
Author's Note: Today's Chart of the Day is for educational purposes only. I want to illustrate that before any M&A is announced to the public, you will sometimes see an individual who has insider information acting on it.
#fbrx #price
2 months ago
The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply toward restocking commercial pipelines with low-risk, high-conviction clinical ******* ets. At the same time, implementation of the Inflation Reduction Act has changed the relative attractiveness of drug options. Since small-molecule drugs are subject to government price negotiations earlier in their lifecycle compared to large-molecule biologics, commercial buyers are shifting premium valuations to large-molecule immunology platforms.
Against this macro context, argenx SE (NASDAQ:ARGX) entered a definitive all-cash agreement on July 27 to acquire clinical-stage biotech Forte Biosciences, Inc. (NASDAQ:FBRX) for $77 per share, valuing the company at over $2.2 billion. At first glance, the $77 offer represents a 40% premium to Forte's closing price prior to the announcement. However, the underlying deal economics demonstrate argenx's readiness to pay a premium for clinical validation: when compared to Forte's volume-weighted average pricing following its successful Phase 1b vitiligo readout on July 9, the purchase price represents an 86% premium.
The target ******* et, Forte's FB102, is a first-in-class anti-CD122 antibody that has shown clinical efficacy in vitiligo and celiac disease. In a 24-week experiment, FB102 showed a significant 29.6% mean improvement on the Facial Vitiligo Area Scoring Index, separating from placebo by day 64.
Argenx's ability to carry out a $2.2 billion cash deal stems from its strong financial condition. The company's Q1 2026 financial report showed global product net sales of $1.3 billion, a 63% increase year-over-year, as well as a quarterly net profit of $366 million and a strong balance sheet with $4.9 billion in cash and financial ******* ets. This commercial momentum is almost exclusively driven by Vyvgart, the company's blockbuster FcRn-blocking medication, which is now seeing its 17th straight quarter of growth.
That said, the explosive top-line trajectory poses a major concentration risk. According to CEO Karen Massey's "Vision 2030" framework, which targets 50,000 patients and ten designated indications worldwide, argenx SE (NASDAQ:ARGX) needs a supplementary second leg in immunology. FB102 offers that diversification by delivering a unique CD122 mechanism into unserved autoimmune indications without jeopardizing its core FcRn business.
#premium #price
Against this macro context, argenx SE (NASDAQ:ARGX) entered a definitive all-cash agreement on July 27 to acquire clinical-stage biotech Forte Biosciences, Inc. (NASDAQ:FBRX) for $77 per share, valuing the company at over $2.2 billion. At first glance, the $77 offer represents a 40% premium to Forte's closing price prior to the announcement. However, the underlying deal economics demonstrate argenx's readiness to pay a premium for clinical validation: when compared to Forte's volume-weighted average pricing following its successful Phase 1b vitiligo readout on July 9, the purchase price represents an 86% premium.
The target ******* et, Forte's FB102, is a first-in-class anti-CD122 antibody that has shown clinical efficacy in vitiligo and celiac disease. In a 24-week experiment, FB102 showed a significant 29.6% mean improvement on the Facial Vitiligo Area Scoring Index, separating from placebo by day 64.
Argenx's ability to carry out a $2.2 billion cash deal stems from its strong financial condition. The company's Q1 2026 financial report showed global product net sales of $1.3 billion, a 63% increase year-over-year, as well as a quarterly net profit of $366 million and a strong balance sheet with $4.9 billion in cash and financial ******* ets. This commercial momentum is almost exclusively driven by Vyvgart, the company's blockbuster FcRn-blocking medication, which is now seeing its 17th straight quarter of growth.
That said, the explosive top-line trajectory poses a major concentration risk. According to CEO Karen Massey's "Vision 2030" framework, which targets 50,000 patients and ten designated indications worldwide, argenx SE (NASDAQ:ARGX) needs a supplementary second leg in immunology. FB102 offers that diversification by delivering a unique CD122 mechanism into unserved autoimmune indications without jeopardizing its core FcRn business.
#premium #price
